

### REMARKS

Claims 26 to 51 are pending in the present application. Claims 29-30, 36-37, 40-41, 44, 46-48 and 51 have been withdrawn from consideration. Applicants reserve the right to pursue previously cancelled subject matter in one or more related applications. No new matter has been added to the application.

Applicants thank the Examiner for her time during the telephone conversation on August 25, 2009. The Examiner clarified that if Applicants elect Group I, Applicants are to elect a species of R<sub>1</sub>, R<sub>2</sub>, X<sub>2</sub>, X<sub>3</sub>, X<sub>4</sub>, X<sub>5</sub>, X<sub>6</sub>, X<sub>7</sub>, Y<sub>1</sub>, Y<sub>2</sub>, Y<sub>3</sub>, Z<sub>1</sub>, Z<sub>2</sub>, L and Ar.

The Office Action issued by Examiner has been carefully reviewed and considered. In the Office Action, Examiner has listed eleven (11) groups as follows:

Group I, claims 26-50 drawn to a chemical compound and a pharmaceutical composition using the compound of formula (I);

Group II, claim 51, drawn to a method of treating obesity using the chemical compound of formula I;

Group III, claim 51, drawn to a method of treating diabetes using the chemical compound of formula I;

Group IV, claim 51, drawn to a method of treating hyperlipidemia using the chemical compound of formula I;

Group V, claim 51, drawn to a method of treating hypertension using the chemical compound of formula I;

Group VI, claim 51, drawn to a method of treating other conditions using the chemical compound of formula I which can be further restricted;

Group VII, claim 51, drawn to a method of preventing obesity using the chemical compound of formula I;

Group VIII, claim 51, drawn to a method of preventing diabetes using the chemical compound of formula I;

Group IX, claim 51, drawn to a method of preventing hyperlipidemia using the chemical compound of formula I;

Group X, claim 51, drawn to a method of preventing hypertension using the chemical compound of formula I;

Group XII, claim 51, drawn to a method of preventing other conditions using the chemical compound of formula I which can be further restricted.

Applicants elect Group I. Applicants further elect the following species:

Ar is a heteroaromatic ring;

Y<sub>1</sub> is a bond;

Y<sub>2</sub> is a lower alkylene;

Y<sub>3</sub> is oxygen;

X<sub>1</sub> is methine;

X<sub>2</sub> is methine;

X<sub>3</sub> is methine;

X<sub>4</sub> is methine;

X<sub>5</sub> is methine;

X<sub>6</sub> is methine;

X<sub>7</sub> is methine;

Z<sub>1</sub> is a bond;

R<sub>2</sub> is methine;

R<sub>1</sub>, L and Z<sub>2</sub> together form an optionally substituted aliphatic nitrogen-containing heterocyclic group;

R<sub>2</sub> is lower alkyl.

Claims 26-28, 31-35, 38-39, 42-43, 45, 49 and 50 read on the above elected species.

CONCLUSION

Applicants earnestly solicit a favorable response from the examiner.

Respectfully submitted,

By /Janet E. Fair, Reg. #56042/  
Janet E. Fair  
No. 56,042  
Attorney for Applicants

MERCK & CO., Inc.  
P.O. Box 2000  
Rahway, New Jersey 07065-0907

Date: August 27, 2009

Tel: (732) 594-6819